Nurix Therapeutics Soars 42.49% on Clinical Data, Partnerships

On July 10, 2025, Nurix Therapeutics experienced a significant surge in its stock price, rising by 42.49% in pre-market trading. This substantial increase reflects the company's recent achievements and strategic advancements in its clinical programs and collaborations.

Nurix Therapeutics recently presented updated data for bexobrutideg (NX-5948) at the European Hematology Association Congress (EHA2025) and the International Conference on Malignant Lymphoma (ICML-18). The data demonstrated a favorable safety profile and deepening responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). This positive clinical data supports the advancement of bexobrutideg into pivotal studies in CLL and underscores its potential to address significant unmet needs in B-cell malignancies.

In addition to its clinical progress, Nurix Therapeutics secured a $15 million license fee from Sanofi as the collaboration for the STAT6 program was extended to target type 2 inflammatory diseases. This extension brings the total received by Nurix under this collaboration to $127 million, with additional milestones and royalties still to be achieved. The STAT6 degrader development candidate, NX-3911, is an oral, highly selective STAT6 degrader that offers a promising therapeutic approach for inflammatory conditions.

Furthermore, Nurix Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for GS-6791/NX-0479, a novel IRAK4 degrader being developed in collaboration with Gilead Sciences. This clearance enables Gilead to initiate Phase 1 trials, marking an important milestone in Nurix's partnership with Gilead and paving the way for the development of degrader-based therapies for autoimmune and inflammatory diseases.

Nurix Therapeutics is well-capitalized with cash and marketable securities of $485.8 million, providing a strong financial foundation to support its ongoing clinical trials and strategic collaborations. The company's continued progress in its clinical programs and collaborations positions it well for future growth and success in the biopharmaceutical industry.